Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Elanco Animal Health IncorporatedNYSE: ELAN
Investing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Investing cash flow declines year over year
Q3 FY2026 investing cash flow of $62M (cash outflow) fell 38.6% year over year, behind the -3.0% change in trailing-twelve-month investing cash flow. Sequentially, it fell 43.6% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Investing cash flow amounted to 5.9% of revenue in FY2025, down 20.2 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -38.6% toward the trailing-twelve-month pace of -3.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (279M) USD
- Year-over-year change
- -124.1%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (279M) | -124.1% |
| FY2024 | 2024-12-31 | 1.16B | +785.2% |
| FY2023 | 2023-12-31 | (169M) | +5.6% |
| FY2022 | 2022-12-31 | (179M) | +66.2% |
| FY2021 | 2021-12-31 | (530M) | — |
Investing Cash Flow vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 investing cash flow of $296M is the 4th largest of the 6 companies compared; the peer median is $335.27M.
- Its year-over-year change of -3.0% is the 4th highest of 6, against a peer median of +50.4%.
- Investing cash flow amounts to 5.7% of revenue for ELAN, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $27.3B | +261.7% | +40.4% | 41.1% | |
| LTM Jun 2026 | $713M | +50.4% | -5.4% | 7.5% | |
| LTM Sep 2026 | $335.27M | +126.6% | -11.3% | 7.2% | |
| LTM Sep 2026 | $296M | -3.0% | +15.9% | 5.7% | |
| LTM Mar 2026 | $62.04M | -78.7% | +133.8% | 4.1% | |
| LTM Aug 2026 | $35.42M | -210.0% | -29.5% | 4.0% | |
| Peer median (excluding ELAN) | $335.27M | +50.4% | -5.4% | 7.2% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (472M) | (78M) | (1.23B) | 338M | (232M) |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| Deferred Income Tax | (154M) | (57M) | (80M) | (112M) | (134M) |
| Stock-Based Compensation | 66M | 59M | 46M | 55M | 68M |
| Change in Working Capital | (87M) | (462M) | (300M) | 149M | 99M |
| Accounts Receivables | (3M) | 14M | (40M) | 12M | (12M) |
| Inventory | 27M | (269M) | (160M) | 44M | (57M) |
| Accounts Payables | (120M) | (98M) | (94M) | 82M | 147M |
| Other Working Capital | 9M | (109M) | (6M) | 11M | 21M |
| Other Non-Cash Items | 414M | 308M | 1.14B | (551M) | 79M |
| Operating Cash Flow | 483M | 452M | 271M | 541M | 560M |
| Capital Expenditures | (197M) | (184M) | (154M) | (147M) | (276M) |
| Acquisitions (Net) | (342M) | 13M | (19M) | 1.32B | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 9M | (8M) | (10M) | (14M) | (3M) |
| Investing Cash Flow | (530M) | (179M) | (169M) | 1.16B | (279M) |
| Debt Repayment | 177M | (517M) | (77M) | (1.48B) | (563M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33M | (32M) | (6M) | (17M) | 288M |
| Financing Cash Flow | 210M | (549M) | (83M) | (1.49B) | (275M) |
| Effect of Forex Changes | (31M) | (17M) | (12M) | (91M) | 71M |
| Net Change in Cash | 132M | (293M) | 7M | 116M | 77M |
| Free Cash Flow | 286M | 268M | 117M | 394M | 284M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.